Lymphoma

Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma.

The combination use of polatuzumab-vedotin, obinutuzumab, and lenalidomide showed high complete response rates in patients with relapsed/refractory follicular lymphoma.

Acalabrutinib alone and in combination with obinutuzumab significantly improved progression-free survival, compared with obinutuzumab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia

First-line treatment with ibrutinib plus venetoclax provided high rates of undetectable minimal residual disease in peripheral blood and bone marrow of patients with chronic lymphocytic leukemia.

Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.

The CAR T-cell therapy axicabtagene ciloleucel induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

The FDA granted a breakthrough therapy designation to abatacept for the prevention of moderate to severe acute graft-versus-host disease in hematopoietic stem cell transplants from unrelated donors.

Research on chimeric antigen receptor T-cell therapy to be presented at the ASH Annual Meeting & Exposition is set to address drawbacks associated with treatment.

MorphoSys announced that their ongoing phase III B-MIND study of tafasitamab passed the interim analysis for futility in patients with relapsed or refractory diffuse large B-cell lymphoma.

As part of Project Orbis, The FDA has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The FDA granted accelerated approval to zanubrutinib for the treatment of adult patients with MCL who have received at least 1 prior therapy.

Overcoming resistance and determining better treatment plans that address the underlying disease biology of mantle cell lymphoma.

Researchers have opened an expansion cohort to include patients with mantle cell lymphoma in the phase I/II CIRLL study to determine if adding cirmtuzumab to ibrutinib can increase the rate of complete remissions.

Biosimilars have shown to be cost-effective treatments in oncology and hematology, according to Jacopo Giuliani, MD.

A new investigational drug called ADCT-402 that combines a cell-killing compound with a monoclonal antibody shows early promise for patients with diffuse large B-cell lymphoma.

The National Comprehensive Cancer Network recently issued new guidelines on best practices in evaluating patients for hematopoietic cell transplantation, as well as how to manage complications associated with the procedure.

Treatment with umbralisib monotherapy demonstrated improved overall response rates among patients with follicular lymphoma.

Jennifer Crombie, MD, discusses classification of diffuse large B-cell lymphoma (DLBCL) into distinct subtypes and treatment decisions based on molecular classifications. 

The epigenetic signals in circulating cell-free DNA (cfDNA) in patients diagnosed with diffuse large B-cell lymphoma (DLBCL) could predict which cases are the most likely to recur.

After conflicting opinions over the years, a study published in the journal Hematology explores the association between diabetes mellitus non-hodgkin lymphoma.

Switching from intravenous to subcutaneous administration of rituximab for non-Hodgkin diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) resulted in similar efficacy with no new safety issues.

The international retrospective study included 365 patients with newly diagnosed early-stage follicular lymphoma rigorously staged with PET-CT and bone marrow biopsy.

MYC-rearrangement within 2 years after diagnosis may affect the prognosis of patients with diffuse large B-cell lymphoma.

A new study looks into whether disease stage at diagnosis affects the occurrence and location of a second primary malignancy in DLBCL.

Prognostic signature associated with AML relapse risk potential harbors gene subsets that apply to only certain patient subgroups.